11/18/2024

Remifentanil Injection

Products Affected - Description

- Ultiva lyophilized powder for injection, Mylan Institutional (Viatris), 5 mg, vial, 10 count, NDC 67457-0198-10
- Remifentanil lyophilized powder for injection, Fresenius Kabi, 1 mg, vial, 10 count, NDC 63323-0723-03
- Remifentanil lyophilized powder for injection, Fresenius Kabi, 2 mg, vial, 10 count, NDC 63323-0724-05
- Remifentanil lyophilized powder for injection, Fresenius Kabi, 5 mg, vial, 10 count, NDC 63323-0725-10
- Remifentanil lyophilized powder for injection, Hikma, 1 mg, vial, 10 count, NDC 00143-9391-10
- Remifentanil lyophilized powder for injection, Hikma, 2 mg, vial, 10 count, NDC 00143-9392-10
- Remifentanil lyophilized powder for injection, Hikma, 5 mg, vial, 10 count, NDC 00143-9393-10

Reason for the Shortage

- Fresenius Kabi has remifentanil on shortage due to increase demand.
- Hikma has remifentanil on shortage due to increase demand.
- Viatris has remifentanil on shortage due to manufacturing delays.

Available Products

- Ultiva lyophilized powder for injection, Mylan Institutional (Viatris), 1 mg, vial, 10 count, NDC 72078-0034-01
- Ultiva lyophilized powder for injection, Mylan Institutional (Viatris), 2 mg, vial, 10 count, NDC 72078-0035-02

Estimated Resupply Dates

- Fresenius Kabi has remifentanil 5 mg vials on back order and the company cannot estimate a release date. The 1 mg and 2 mg vials are on back order and the company estimates a release date of late-January 2025.
- Hikma has remifentanil 1 mg, 2 mg, and 5 mg vials on back order and the company estimates a release date of late-February 2025.
- Viatris has Ultiva 5 mg vials on back order and the company estimates a release date of February 2025.

Updated

Updated November 18, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 22, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.